Oracle Investment Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-6,633
Closed -$526K 30
2022
Q3
$526K Buy
+6,633
New +$559K 0.3% 17
2021
Q3
Sell
-76,200
Closed -$10.3M 44
2021
Q2
$10.3M Buy
+76,200
New +$10M 1.42% 13

Other funds holding XBI

Oracle Investment Management's XBI Position: Q4 2022 in Review

Oracle Investment Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2022, closing a stake of 6,633 shares — an estimated $526K sold.

Oracle Investment Management first reported a position in XBI in Q2 2021 and held it in 2 quarters. The position peaked at $10.3M in Q2 2021. 746 funds tracked by Wall St. Rank hold XBI as of Q4 2022.

  • Oracle Investment Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2022 after selling out during the quarter.
  • Oracle Investment Management sold 6,633 State Street SPDR S&P Biotech ETF shares in Q4 2022, an estimated $526K.
  • Oracle Investment Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and held it in 2 quarters.
  • Oracle Investment Management's State Street SPDR S&P Biotech ETF position peaked at $10.3M in Q2 2021.
  • 746 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2022.

Based on Oracle Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.